Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Notes from the Field: Adverse Events Following a Mass Yellow Fever Immunization Campaign — Kongo Central Province, Democratic Republic of the Congo, September 2016

Weekly / March 31, 2017 / 66(12);343–344


Article Metrics

Views equals page views plus PDF downloads

Views:

Citations:

Altmetric:

Metric Details

John O. Otshudiema, MD1,2; Nestor G. Ndakala, MD3; Maurice L. Loko, MD4; Elande-taty K. Mawanda, MD5; Gaston P. Tshapenda, MD6; Jacques M. Kimfuta, MD5; Abdou S. Gueye, MD, PhD7; Jacob Dee, MPH8; Rossanne M. Philen, MD7; Coralie Giese, MA, MPH7; Christopher S. Murrill, PhD9; Ray R. Arthur, PhD7; Benoit I. Kebela, MD6 (View author affiliations)

View suggested citation

On April 23, 2016, the Democratic Republic of the Congo (DRC) Ministry of Health reported an outbreak of yellow fever. As of May 24, 2016, among 41 confirmed yellow fever cases, 31 (75.6%) had occurred in Kongo Central Province, in the western part of the country bordering Angola (1), where a large yellow outbreak had begun in December 2015. In response, during May 25–June 7, 2016, the DRC Ministry of Health administered approximately 240,000 doses of yellow fever vaccine to all persons aged ≥9 months during a mass vaccination campaign in Matadi, one of 31 health zones in the Kongo Central Province. The administrative vaccination coverage (i.e., the number of vaccine doses administered divided by the most recent census estimates for the target population), was estimated to have reached >99%.

During the campaign, health workers in the Matadi Health Zone were trained to identify adverse events following immunization (AEFIs), complete case report forms, and send forms weekly to both provincial officials and a national expert committee for vaccine pharmacovigilance. Although a provisional classification of AEFIs by severity is made at peripheral and provincial levels at the time of an initial investigation, responsibilities at the national level are to guide the investigation of suspected serious AEFIs, classify them according to standard AEFI cause–specific definitions, recommend additional testing of biologic specimens if warranted, and determine causality.

Because identification of AEFIs through passive surveillance is limited by low reporting rates in Kongo Central Province (estimated <50%), active surveillance (review of hospital records and interviews with health care personnel) for AEFIs after receipt of yellow fever vaccine was piloted in the Matadi Health Zone after the campaign. Results obtained through active surveillance were compared with the results from the existing routine passive AEFI reporting system integrated into the Expanded Program on Immunization (EPI), which was established in the late 1970s to ensure that infants/children and mothers have access to routinely recommended vaccines.

An AEFI was defined for both the passive and active surveillance programs as any untoward medical occurrence (reported by either the vaccine recipient or a health worker) that occurs after immunization (≤30 days after the receipt of yellow fever vaccine) and which is not necessarily causally related to receipt of the vaccine. An active retrospective search to identify AEFIs was conducted at two referral health facilities in the Matadi Health Zone. Data were collected using the national EPI AEFI case investigation form, which was revised based on recommendations in the World Health Organization’s field guide, Surveillance of Adverse Events Following Immunization Against Yellow Fever (2). Trained EPI health zone and provincial surveillance supervisors identified potential AEFI cases through review of hospital registries and medical charts and interviews with emergency department personnel and community health workers. At the peripheral and provincial levels, identified AEFIs were provisionally classified as serious or nonserious. Serious AEFIs included those resulting in death, hospitalization or prolongation of hospitalization, persistent or major disability/incapacity; those that were life-threatening; or those that represented a congenital anomaly/birth defect in an infant after vaccination of the mother during pregnancy. All other AEFIs were classified as nonserious (3).

AEFIs identified through this comprehensive review were compared with those detected through passive surveillance during the immunization campaign to assess the completeness and representativeness of passive surveillance data. Overall, 15 AEFIs were identified by active surveillance among approximately 2,800 patient records reviewed at the two targeted referral hospitals, including eight AEFIs previously reported during the immunization campaign (Table). Two AEFIs were classified as serious and 13 as nonserious. The serious AEFIs comprised a spontaneous abortion that occurred after inadvertent administration of yellow vaccine early during an unrecognized pregnancy and a nonspecific gastrointestinal syndrome, both resulting in prolonged hospitalizations. Nonserious AEFIs included cutaneous allergic reactions, itching, fever, and injection site erythema. The incidences were 6.2 per 100,000 vaccine doses administered for all identified AEFIs and 0.8 for serious AEFIs. The AEFI incidence rate using the previous passive EPI surveillance data was 3.3 per 100.000 vaccine doses administered. Previous studies in African settings have found an expected AEFI rate of 8.2 per 100,000 yellow fever vaccine doses administered for all reported AEFIs and 0.4 for any serious AEFI (4).

This enhanced surveillance program found that the passive yellow fever AEFI system failed to identify half of all AEFIs that were identified through active surveillance, including all of the serious AEFIs. The national expert committee for vaccine pharmacovigilance will validate all AEFIs identified through this evaluation; however, discrepancies between AEFIs identified through this pilot active surveillance and through passive surveillance highlight the need for an organized and active data collection system to supplement the lack of sensitivity of passive AEFI detection during a mass immunization campaign (2,3).

Acknowledgments

Kongo Central Health Zone and Health Facility officials and providers; Adverse Events Following Immunization Investigation Team and Kongo Central Expanded Program on Immunization staff members; members of the Working Group (Medical Director of Kinkanda Provincial General Hospital, Medical Chief and Nurse Supervisor of Matadi Health Zone, and Provincial Medical Coordinator of Kongo Central Kongo Central Expanded Program on Immunization).

Corresponding author: John O. Otshudiema, jotshudiema@cdc.gov, 404-639-4719.

1Epidemic Intelligence Service Program, CDC; 2Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC; 3Field Epidemiology and Laboratory Training Program, Kinshasa, Democratic Republic of the Congo; 4Programme Elargi de Vaccination (Expanded Program on Immunization), Division Provinciale de la Santé, Kongo Central Province, Ministry of Health, Democratic Republic of the Congo; 5Division Provinciale de la Santé, Kongo Central Province, Ministry of Health, Democratic Republic of the Congo; 6Direction de Lutte Contre la Maladie, Ministry of Health, Kinshasa, Democratic Republic of the Congo; 7Division of Global Health Protection, Center for Global Health, CDC; 8Division of Global HIV and TB, Center for Global Health, CDC; 9Global Immunization Division, Center for Global Health, CDC.

References

  1. World Health Organization. Democratic Republic of Congo Ministry of Health. Situation report of yellow fever in the Democratic Republic of Congo, May 25, 2016 [French]. Geneva, Switzerland: World Health Organization; 2016. http://www.who.int/emergencies/yellow-fever/situation-reports/Sitrep_Fievre_Jaune_RDC_25mai2016.pdf
  2. World Health Organization. Surveillance of adverse events following immunization against yellow fever: field guide for staff at the central, intermediate and peripheral level. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/csr/resources/publications/HSE_GAR_ERI_2010_1ENw.pdf
  3. Council for International Organizations of Medical Sciences (CIOMS). Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Working Group on vaccine pharmacovigilance. Geneva, Switzerland: World Health Organization; 2012. http://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf
  4. Breugelmans JG, Lewis RF, Agbenu E, et al. YF AEFI group. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013;31:1819–29. CrossRef PubMed
Return to your place in the textTABLE. Adverse events following immunization (AEFIs) after a mass yellow fever vaccination campaign, identified through active surveillance system — Matadi Health Zone, Kongo Central Province, Democratic Republic of the Congo, September 2016
Patient Sex Age (yrs) Date reported Vaccine receipt to onset (days) Description of AEFI (other associated medical conditions)* Provisional classification peripheral level Outcome
1† F 23 5/27/2016 2 Cutaneous allergic reaction, rash, itching Nonserious Recovered
2 M 16 5/28/2016 3 Unexplained fever Nonserious Recovered
3 M 25 5/28/2016 2 Gastrointestinal syndrome, vomiting, fever Nonserious Recovered
4† M 59 5/30/2016 2 Cutaneous allergic reaction, rash, itching Nonserious Recovered
5† F 36 5/30/2016 2 Injection-site pain and erythema, tiredness, muscle pain Nonserious Recovered
6 M 3 5/30/2016 3 Undetermined hematuria and tiredness Nonserious Recovered
7† F 26 5/31/2016 2 Cutaneous allergic reaction, rash, itching Nonserious Recovered
8† F 49 5/31/2016 2 Cutaneous allergic reaction, rash, itching Nonserious Recovered
9† F 14 5/31/2016 2 Cutaneous allergic reaction, rash, itching, fever Nonserious Recovered
10† F 45 5/31/2016 2 Cutaneous allergic reaction, rash, itching, allergic reaction on lips Nonserious Recovered
11† M 29 6/1/2016 2 Cutaneous allergic reaction, rash, itching, injection site pain and erythema Nonserious Recovered
12 F 25 6/1/2016 3 Allergic reaction on lips Nonserious Recovered
13 F 7 6/2/2016 2 Gastrointestinal syndrome, muscle pain, injection-site pain and erythema (severe malaria and urinary tract infection) Serious Recovered after 7-day hospitalization
14 M 17 6/4/2016 2 Eye allergic reaction, conjunctivitis Nonserious Recovered
15 F 22 6/11/2016 5 Spontaneous abortion of an unrecognized early pregnancy (endometritis) Serious Recovered after 7-day hospitalization

Abbreviations: AEFI = adverse event following immunization; F = female; M = male.
* Descriptions based on the Expanded Program on Immunization AEFI investigation forms, which were revised based on recommendations in the World Health Organization field guide for surveillance of AEFIs following yellow fever vaccination.
† Detected by the routine passive surveillance system.

Suggested citation for this article: Otshudiema JO, Ndakala NG, Loko ML, et al. Notes from the Field: Adverse Events Following a Mass Yellow Fever Immunization Campaign — Kongo Central Province, Democratic Republic of the Congo, September 2016. MMWR Morb Mortal Wkly Rep 2017;66:343–344. DOI: http://dx.doi.org/10.15585/mmwr.mm6612a7.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

Format:
TOP
window.CDC.Policy.External.init();